We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 38% below its sector, cheaper than its peers on earnings.
Hunan Jiudian Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that spans the entire value chain from drug discovery and development to manufacturing and commercialization. The company's extensive product line includes medications for treating allergies, infections, and inflammatory conditions, as well as analgesics and gynecological remedies. Their offerings further extend to products for digestive health, both Western chemical drugs and traditional Chinese patent medicines, medical equipment, and Active Pharmaceutical Ingredients (APIs). Additionally, Hunan Jiudian provides contract manufacturing services for various pharmaceutical formulations, such as tablets, capsules, granules, and oral liquid preparations like solutions and syrups. The company is headquartered in Changsha, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300705.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
